You don't need surgery for that tendon.
BPC-157 was discovered in human gastric juice — your body already produces a related form of it. When researchers injected it near damaged tendons, new blood vessels grew. Tenocytes migrated toward the injury. Tissue that hadn't healed in months started healing in weeks. The mechanism is angiogenesis and growth factor upregulation. What matters: people with chronic tendonitis, rotator cuff tears, and ligament damage that hadn't improved for months saw real improvement. This is a signaling peptide your body understands. Not a supplement. Not a drug. A signal.
BPC-157
Body Protection Compound 157
BPC-157 is a synthetic peptide studied for its ability to accelerate repair in tendons, ligaments, muscles, and bone. What makes it different from most recovery protocols is its primary mechanism: it stimulates angiogenesis — the growth of new blood vessels — directly into damaged tissue, feeding cells the oxygen and nutrients they need to rebuild. Originally discovered in human gastric juice, this 15-amino-acid compound has been the subject of dozens of preclinical studies and case reports across orthopaedics and sports medicine. Here is what the research actually shows.
Technical details
- CAS number
- 137525-51-0
- Molecular formula
- C62H98N16O22
MECHANISM OF ACTION
At the core of BPC-157's repair activity is **angiogenesis** — the formation of new blood vessels. The peptide upregulates **VEGF** (vascular endothelial growth factor), a signalling protein that tells endothelial cells to build fresh capillaries directly into the injury site. Why this matters: blood delivers oxygen, nutrients, and immune cells. A tendon or ligament with poor blood supply heals slowly, if at all. By driving new vessel growth, BPC-157 gives damaged tissue the raw materials it needs to rebuild. But angiogenesis is only part of the picture. BPC-157 also enhances **growth hormone receptor expression** in tenocytes — the cells responsible for tendon structure and repair. More receptors mean tenocytes become more responsive to the body's own repair signals, accelerating migration to the injury site and boosting collagen production. In preclinical models, this translates to faster, more complete tendon-to-bone healing. The peptide exerts potent **anti-inflammatory effects** through the nitric oxide (NO) system, modulating the inflammatory response rather than suppressing it entirely. This helps control secondary damage from prolonged inflammation while preserving the early inflammatory signals that kickstart repair. Against corticosteroid-induced tissue damage — a known problem in sports medicine where cortisone injections weaken adjacent tissue — BPC-157 has shown protective effects in animal models, maintaining tissue integrity where it would otherwise degrade.
RESEARCH HIGHLIGHTS
BPC-157 significantly accelerated tendon-to-bone healing in a rat Achilles tendon detachment model and counteracted the tissue-weakening effects of corticosteroids.
The peptide promotes tendon healing by stimulating tenocyte outgrowth, enhancing cell survival, and increasing cell migration to the repair site.
BPC-157 upregulates growth hormone receptors in tendon fibroblasts, making tendon cells more responsive to the body's natural repair signalling.
Pro-angiogenic effects were confirmed in both muscle and tendon healing, with increased blood flow delivered directly to the site of tissue damage.
A comprehensive review confirmed that BPC-157 consistently accelerates healing across multiple tissue types — tendon, ligament, muscle, and bone — in preclinical models.
RESEARCH PROTOCOLS
For laboratory use only. Not medical advice.
Start low, listen to your body. This is the safest entry point if you are blood-pressure-sensitive.
Inject subcutaneously in abdominal tissue, or closer to the injury site — for example, the anterior deltoid for rotator cuff issues. Effects may persist 2+ weeks post-cycle.
For severe or chronic conditions — full-thickness tears, long-standing tendinopathy that has not responded to other interventions. Stack with TB-500 for a synergistic recovery effect.
PAIRS WELL WITH
ORDER
SAFETY & CONTRAINDICATIONS
- History of cancer (theoretical angiogenic concern — use with caution)
- Pregnancy or breastfeeding (insufficient data)
- Known hypersensitivity to peptide components
- Active autoimmune disease (limited data)
BPC-157 is generally well-tolerated in research settings, but there are a few effects worth knowing about. The most commonly reported is a reduced tolerance to alcohol and caffeine — you may feel the effects of a drink or coffee more strongly than usual. Rather than a side effect, many researchers consider this a signal that the peptide is interacting with your system. It is harmless and reverses after the cycle ends. Some users report a temporary increase in blood pressure at higher starting doses, particularly above 500 mcg per administration. If you are sensitive to BP changes, begin with the lower protocol and monitor — most cases resolve as the body adjusts. Positive effects reported anecdotally include improved sleep quality and increased libido. Because BPC-157 has not been studied in long-term human trials beyond 6–8 week cycles, the long-term safety profile is not yet established. Research is ongoing.
For research and laboratory use only. Not intended for human consumption. Not for diagnostic or therapeutic purposes.